| Literature DB >> 30340430 |
Markus Bo Schoenberg1, Jingcheng Hao2,3, Julian Nikolaus Bucher4, Rainer Christoph Miksch5, Hubertus Johann Wolfgang Anger6, Barbara Mayer7, Julia Mayerle8, Jens Neumann9, Markus Otto Guba10,11, Jens Werner12,13, Alexandr V Bazhin14,15.
Abstract
Liver resection is a curative treatment for hepatocellular carcinoma (HCC). Tumor-infiltrating leukocytes (TILs) are important players in predicting HCC recurrence. However, the invasive margin could not be confirmed as relevant for HCC. The migration of immune cells into HCC may originate from intratumoral vessels. No previous study has examined perivascular (PV) infiltration. Tumors from 60 patients were examined. Immunohistochemistry was performed against CD3, CD8, CD20, and CD66b. TILs were counted in the PV regions using an algorithm for quantification of the tumor immune stroma (QTiS). The results were correlated with overall (OS) and disease-free survival (DFS), clinical parameters, and laboratory values. PV infiltration of TILs was predominant in resected HCC. Higher PV infiltration of CD3⁺ (p = 0.016) and CD8⁺ (p = 0.028) independently predicted better OS and DFS, respectively. CD20⁺ showed a trend towards better DFS (p = 0.076). Scoring of CD3⁺, CD8⁺, and CD20⁺ independently predicted OS and DFS (p < 0.01). The amount of perivascular-infiltrating CD3⁺ cells is an independent predictor of better OS, and CD8⁺ cells independently predict prolonged DFS. Our novel perivascular infiltration scoring (PVIS) can independently predict both DFS and OS in resected HCC patients.Entities:
Keywords: hepatocellular carcinoma; immunology; liver resection; quantification of the tumor immune stroma (QTiS); tumor-infiltrating leukocytes
Year: 2018 PMID: 30340430 PMCID: PMC6210365 DOI: 10.3390/cancers10100389
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Demographics of the Study Population.
| Variables | Results |
|---|---|
| Gender (Male/Female) | 49 (81.7%)/11 (18.3%) |
| Age (Years) (Median (IQR)) | 66.00 (16.00) |
| Hepatitis (HBV/HCV) | 7 (11.7%)/0 (0.0%) |
| Cirrhosis | 15 (25.0%) |
| AFP (ng/mL) (Median (IQR)) | 12.60 (153.00) |
| Tumor multiplicity | 9 (15.0%) |
| Microvascular invasion | 18 (30.0%) |
| Macrovascular invasion | 6 (10.0%) |
| Beyond Milan Criteria | 47 (78.3%) |
| Bilirubin (mg/dL) (Median (IQR)) | 0.70 (0.30) |
| Albumin (mg/dL) (Median (IQR)) | 43.00 (5.00) |
| ALT (U/L) (Median (IQR)) | 42.00 (33.00) |
| AST (U/L) (Median (IQR)) | 45.00 (37.00) |
| APTT (s) (Median (IQR)) | 28.50 (5.25) |
| Creatinine (mg/dL) (Median (IQR)) | 1.00 (0.20) |
| CRP (mg/L) (Median (IQR)) | 6.00 (16.00) |
| Leukocytes (103/µL) (Median (IQR)) | 7246.67 (2094.03) |
| Platelets (103/µL) (Median (IQR)) | 222.00 (120.50) |
Abbreviations: IQR, Interquartile Range; HBV, hepatitis B; HCV, hepatitis C; AFP: serum alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; AJCC: American Joint Committee on Cancer; ALT: alanine transaminase; AST: aspartate transaminase; APTT: activated partial thromboplastin time; CRP: C-reactive protein.
Figure 1Overall (A) and Disease-free Survival (B) of All Patients.
Figure 2Representative Perivascular Patterns of CD3+, CD8+, CD20+, and CD66b+ Cells under 50×, 100×, and 200× Magnifications. (A) CD3 at 50× magnification; (B) CD3 at 100× magnification; (C) CD3 at 200× magnification; (D) CD8 at 50× magnification; (E) CD8 at 100× magnification; (F) CD8 at 200× magnification; (G) CD20 at 50× magnification; (H) CD20 at 100× magnification; (I) CD20 at 200× magnification; (J) CD66b at 50× magnification (K) CD66b at 100× magnification; (L) CD66b at 200× magnification.
Figure 3Kaplan-Meier Curves of CD3+ (A), CD8+ (B), CD20+ (C), and CD66+ (D) cells for DFS. (E) Cox Regression Curves of CD3+ cells on OS (Overall Survival) with Collett’s Model for Selection of Covariates. (F) Cox Regression Curves of CD8+ cells on DFS (Disease Free Survival) with Collett’s Model for Selection of Covariates.
Univariate Analysis of All Factors on OS and DFS in all Hepatocellular Carcinoma (HCC) Patients (n = 60).
| Variables | Overall Survival | Disease-free Survival | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |||
| Gender | 1.243 | 0.781 | 1.978 | 0.355 | 2.312 | 1.112 | 4.808 |
|
| Age (≥60 years) | 0.440 | 0.150 | 1.291 | 0.124 | 1.496 | 0.754 | 2.971 | 0.246 |
| Hepatitis | 0.237 | 0.077 | 0.732 |
| 2.451 | 0.932 | 6.447 |
|
| Cirrhosis | 0.525 | 0.219 | 1.256 | 0.141 | 0.843 | 0.399 | 1.779 | 0.652 |
| AFP (≥20 ng/mL) | 0.913 | 0.389 | 2.145 | 0.835 | 0.638 | 0.322 | 1.266 |
|
| AFP (≥400 ng/mL) | 1.798 | 0.420 | 7.706 | 0.423 | 1.364 | 0.478 | 3.889 | 0.560 |
| Tumor Multiplicity | 1.521 | 0.355 | 6.517 | 0.570 | 0.818 | 0.339 | 1.973 | 0.653 |
| Microvascular Invasion | 0.677 | 0.272 | 1.690 | 0.401 | 0.708 | 0.346 | 1.447 | 0.338 |
| Macrovascular Invasion | 0.702 | 0.201 | 2.457 | 0.578 | 0.618 | 0.232 | 1.644 | 0.328 |
| Beyond Milan | 0.553 | 0.073 | 4.187 | 0.560 | 0.272 | 0.037 | 2.006 |
|
| Low CD3+ Cells | 2.196 | 0.956 | 5.046 |
| 2.277 | 1.145 | 4.527 |
|
| Low CD8+ Cells | 1.531 | 0.684 | 3.425 | 0.297 | 2.074 | 1.064 | 4.043 |
|
| Low CD20+ Cells | 1.291 | 0.574 | 2.904 | 0.535 | 0.549 | 0.279 | 1.079 |
|
| Low CD66b+ Cells | 1.228 | 0.550 | 2.744 | 0.616 | 1.239 | 0.641 | 2.394 | 0.521 |
Abbreviations: HR: Hazard ratio; CI: confidence interval; p: p-value; AFP: serum alpha-fetoprotein; HCC: Hepatocellular Carcinoma. The p-values under 0.200 are bolded.
Figure 4Kaplan-Meier Curves of Scoring on (A) overall survival (OS) and (B) disease-free survival (DFS). (C) Cox Regression Curves of Scoring on DFS with Collett’s Model for Selection of Covariates. (D) Cox Regression Curves of Scoring on OS with Collett’s Model for Selection of Covariates.